NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

0.6750

-0.0046

(-0.68%)

At close: 04:00PM EDT

0.6601

-0.01

(-2.21%)

After hours:

07:48PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	0.6796
Open	0.6800
Bid	0.6502 x 1100
Ask	0.6794 x 3200
Day's Range	0.6500 - 0.6800
52 Week Range	0.6500 - 12.6000
Volume	155,081
Avg. Volume	448,033

Market Cap	1.842M
Beta (5Y Monthly)	2.73
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NBY

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Press Releases

Business Wire
NovaBay Pharmaceuticals to Present at the Emerging Growth Virtual Conference on May 31, 2023
EMERYVILLE, Calif., May 24, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, Chief Executive Officer, will present a company overview at the Emerging Growth Virtual Conference on Wednesday, May 31, 2023 at 1:10 p.m. Eastern time (10:10 a.m. Pacific time).
Business Wire
NovaBay Pharmaceuticals Reports First Quarter 2023 Financial Results
EMERYVILLE, Calif., May 11, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2023 and provides a business update.
Business Wire
PhaseOne Health Collaborates with Nonprofit Humanitarian Organization to Supply NovaBay Pharmaceuticals’ Phase One® Skin and Wound Cleanser to Ukraine
NASHVILLE, Tenn. & EMERYVILLE, Calif., May 05, 2023--PhaseOne Health announces it has provided PhaseOne Skin and Wound Cleanser (PhaseOne) as part of a $3 million donation of medical supplies to Ukraine in partnership with the nonprofit HelpingUkraine.us. Formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid, PhaseOne (0.025% hypochlorous acid solution) is a proprietary wound care product used for cleansing and irrigation as part of surgical procedures,
Business Wire
NovaBay Pharmaceuticals to Hold First Quarter 2023 Conference Call on May 11, 2023
EMERYVILLE, Calif., May 04, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Business Wire
NovaBay Pharmaceuticals Fulfills $1 Million Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings
EMERYVILLE, Calif., May 01, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading Chinese importer and marketer of branded pharmaceuticals and medical devices, has placed a $1 million order for NovaBay’s NeutroPhase Skin and Wound Cleanser. NovaBay has fulfilled this order and expects to recognize this revenue in the second quarter of 2023.
Business Wire
NovaBay Pharmaceuticals Announces $3.0 Million Convertible Note Financing
EMERYVILLE, Calif., April 27, 2023--NovaBay Pharmaceuticals announces $3.0 Million Convertible Note Financing
Business Wire
NovaBay Pharmaceuticals Launches DERMAdoctor’s New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on the QVC® Network
EMERYVILLE, Calif., April 21, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer and board-certified dermatologist Audrey Kunin, MD will introduce the new DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream with 3% Salicylic Acid as an on-air guest on the QVC network. The new product for the treatment and relief of symptoms of psoriasis will
Business Wire
NovaBay Pharmaceuticals Reports 2022 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif., March 30, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2022 and provides a business update. Financial results for 2022 include DERMAdoctor®, which NovaBay acquired on November 5, 2021.
Business Wire
NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023
EMERYVILLE, Calif., March 23, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Business Wire
Eyeganics Organic Tears, the Only USDA-Certified Organic Lubricant Eye Drop, Now Available through NovaBay Pharmaceuticals’ Avenova.com and Physician-Dispensed Channel
EMERYVILLE, Calif. & KIRKWOOD, Mo., March 14, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed channel. Organic Tears has no additives or artificial chemicals and is the only lubricant eye drop certified by the USDA as 100% organic and preservative-free.
Business Wire
NovaBay Pharmaceuticals Launches Avenova® Eye Health Support, a New Antioxidant-Rich Oral Supplement to Comfort Dry Eyes and Promote Overall Eye Health
EMERYVILLE, Calif., March 07, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright®, a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and high quality, natural triglyceride omega-3 oils to comfort dry eyes and support overall eye health.
Business Wire
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor’s Eczema Treatment on Two QVC® Shows on February 7
EMERYVILLE, Calif., February 06, 2023--NovaBay announces DERMAdoctor's Eczema Treatment to be featured on Two QVC® Shows on February 7
Business Wire
NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
EMERYVILLE, Calif., January 31, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website.
Business Wire
PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market
NASHVILLE, Tenn. & EMERYVILLE, Calif., January 17, 2023--PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid.
Business Wire
NovaBay Pharmaceuticals Announces the Launch of DERMAdoctor’s TikTok Store in China and Expands Online Marketing in the U.S. and China
EMERYVILLE, Calif., November 29, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the expansion of its lifestyle promotional video campaigns on TikTok and its Chinese counterpart Douyin to reach new customers for its Avenova® and DERMAdoctor® brand products.
Business Wire
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor’s Eczema Balm
EMERYVILLE, Calif., November 17, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network. Dr. Kunin will discuss DERMAdoctor’s moisturizing Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on "Give Gorgeous – Gifts With Purchase" hosted by two
Business Wire
NovaBay Pharmaceuticals Reports Third Quarter 2022 Financial Results
EMERYVILLE, Calif., November 14, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business update. Financial results for the first nine months of 2022 include DERMAdoctor, which NovaBay acquired on November 5, 2021.
Business Wire
NovaBay Pharmaceuticals Announces 1-for-35 Reverse Stock Split
EMERYVILLE, Calif., November 14, 2022--NovaBay® Pharmaceuticals, Inc. (the "Company") (NYSE American: NBY) announces that today, following approval from the Company’s stockholders obtained at the Company’s November 10, 2022 special stockholders’ meeting, the Company’s Board of Directors (the "Board") has approved the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a 1-for-35 reverse stock split of all outstanding shares of common s
Business Wire
NovaBay Pharmaceuticals to Hold Third Quarter 2022 Conference Call on November 14
EMERYVILLE, Calif., November 09, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Business Wire
NovaBay Pharmaceuticals Announces Expansion of DERMAdoctor Picture Porefect Collection with Launch of 15% Niacinamide Pore Minimizing Serum
EMERYVILLE, Calif., October 26, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the newest addition to the DERMAdoctor® Picture Porefect® collection: 15% Niacinamide Pore Minimizing Serum. This new, high-potency formulation minimizes the size of visible facial pores while delivering free-radical-neutralizing antioxidants and collagen-supporting agents to reduce blackheads, skin discoloration, rough skin, acne, and oily or combination skin.
Business Wire
NovaBay Pharmaceuticals to Present at the LD Micro Main Event XV
EMERYVILLE, Calif., October 19, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present a company overview at the LD Micro Main Event XV on Wednesday, October 26 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.
Business Wire
NovaBay Pharmaceuticals Announces Significant Orders for DERMAdoctor’s Top-Selling Kakadu C Anti-Aging Serum ahead of the Holiday Season
EMERYVILLE, Calif., October 18, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces significant orders for DERMAdoctor® Kakadu® C 20% Vitamin C Serum with Ferulic Acid & Vitamin E.
Business Wire
NovaBay Pharmaceuticals’ Avenova® and DERMAdoctor® Products to be Featured During the October 11-12 Amazon Prime Early Access Sale
EMERYVILLE, Calif., October 10, 2022--NovaBay Pharmaceuticals' Avenova and DERMAdoctor products featured during Amazon Early Access Prime event.
Business Wire
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Low Share Price
EMERYVILLE, Calif., October 07, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Company’s common stock has been selling for a low price per share for a substantial period of time. As a result, pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the Company must effect a reverse stock split of its common stock or otherwise demonstrate sustained price improvement within a reasonable
Business Wire
NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
EMERYVILLE, Calif., September 23, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). The conference is being held at the Sofitel Hotel New York. A webcast of the presentation will be available on